Endonovo Therapeutics Inc (ENDV)

[brand0nnn]

NEW ARTICLE out today - Bill Gates Dedicates $30M into Alzheimer’s Treatments

HENDERSON, NV / ACCESSWIRE / July 23, 2018 / Along with several other philanthropists, Bill Gates recently announced he is putting $30 million into the Diagnostics Accelerator, a “venture philanthropy” fund to develop early diagnostic procedures and bring them to market quickly.

One small Alzheimer related biotech firm on our radar is Endonovo Therapeutics, Inc. (ENDV). ENDV could be just one little push from a massive inflection point. This company has traded well over 300% higher in the last year. There was a massive rush into ENDV last October, and smart, risk tolerant investors could take advantage of this opportunity.

Gates hopes to get Alzheimer’s patients diagnosed earlier.

Alzheimer’s is a brain disease that affects memory, motor functions, and eventually, a person’s ability to function properly in daily life. If you live to 85 – which is not uncommon in the modern world – you have a one-third chance of developing the disease, according to the Alzheimer’s Association. As the US population ages, the disease is expected to affect 13.8 million by 2050.

At the beginning of the year, several companies started giving up on treating the disease. However, many still remain in the space, and could benefit from Gates’ crusade against the disease.

Endonovo Therapeutics, Inc. (ENDV)

Market cap: $11.649 million; current share price: $0.0332

Endonovo Therapeutics, Inc. (ENDV), a commercial-stage developer of Electroceutical™ Therapies, recently announced that the first patient has been enrolled in a clinical study at the University of New Mexico Health Sciences Center that will evaluate the effects of Pulsed Electromagnetic Fields (PEMF) on reducing brain injury, blood-brain-barrier and inflammation biomarkers in the cerebrospinal fluid and blood in patients with brain injury who are or have been fitted to an external ventricular drain. Funding for the study has been secured via the Company’s senior secured Series C Preferred Stock financing.

“The initiation of this study represents a significant milestone for Endonovo,” said Endonovo CEO, Alan Collier. “We believe our technology, whose proven mechanism of action is the suppression of inflammation, has the potential to change the treatment of central nervous system disorders where neuroinflammation propagates injury such as ischemic stroke, Alzheimer’s disease and Multiple Sclerosis.”

http://www.wmcactionnews5.com/story/38706520/bill-gates-dedicates-30m-into-alzheimers-treatments